Pharmacogenetics

Chair

Jesse Swen
Lieden, Netherlands

Vice-Chair

Erika Cecchin
Aviano, Italy

Committee Purpose

  • To promote the knowledge about clinically relevant DNA testing to optimize drug therapy
  • To enhance the translation of research into clinical practice
  • To encourage discussions on the clinical relevance of specific pharmacogenetics tests, to encourage research into clinically important areas with respect to drug treatment
  • To encourage interaction between pharmacologist and toxicologist to promote “toxicogenetics”

2021

Make proposal for IATDMCT PGx session in the next Congress.

Propose/validate a (minimal) NGS panel to be used for pharmacogenetic applications in the field of TDM and CT (to be published in IATDMCT Compass).

Explore the need for updated PGx guidelines in immunosuppressive therapy.

Increase membership.

2019

Informed members of IATDMCT on current discussions regarding PGx testing, on new potentially interesting pharmacogenetic markers, and the emergence of new technologies.

Organization of 2 PGx sessions in Foz do Iguaçu 2019

Morning session PGx on Tamoxifen (23/09/2019), Dr J. Swen and Dr Y. Tanigawara

Symposium on PGx in oncology (25/09/2019) DPYD and 5-FU, Dr T. van Gelder; UGT1A1 and beyond, Dr J.C. Boyer; ABCG2 and TKIs Dr T. Terada.

2021

Haufroid V, Picard N. Pharmacogenetics Biomarkers Predictive of Drug Pharmacodynamics as an Additional Tool to Therapeutic Drug Monitoring. Ther Drug Monit. 2019 Apr;41(2):121-130. doi: 10.1097/FTD.0000000000000591. PMID: 30883506.

2019

Brunet M, van Gelder T, Åsberg A, Haufroid V, Hesselink DA, Langman L, Lemaitre F, Marquet P, Seger C, Shipkova M, Vinks A, Wallemacq P, Wieland E, Woillard JB, Barten MJ, Budde K, Colom H, Dieterlen MT, Elens L, Johnson-Davis KL, Kunicki PK, MacPhee I, Masuda S, Mathew BS, Millán O, Mizuno T, Moes DAR, Monchaud C, Noceti O, Pawinski T, Picard N, van Schaik R, Sommerer C, Vethe NT, de Winter B, Christians U, Bergan S. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Ther Drug Monit. 2019 Jun;41(3):261-307. doi: 10.1097/FTD.0000000000000640. PMID: 31045868.

Compass submissions:

  • Haufroid V and Picard N on behalf of the Pharmacogenetics Committee. Genotyping versus Phenotyping: The case of fluoropyrimidines. IATDMCT Compass June 2019: 9-10.

2018

Compass submissions:

  • Picard N and Haufroid V on behalf of the Pharmacogenetics Committee. Physician and pharmacist awareness and education about pharmacogenetics: The next challenge for clinical implementation? IATDMCT Compass December 2018: 9-10.
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.